Get the Stockscreener App
3.65
2.24%
0.08
After Hours:
3.80
0.15
+4.11%
Evotec Se Adr stock is traded at $3.65, with a volume of 122.09K.
It is up +2.24% in the last 24 hours and down -3.18% over the past month.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
See More
Previous Close:
$3.57
Open:
$3.58
24h Volume:
122.09K
Relative Volume:
1.39
Market Cap:
$1.29B
Revenue:
$853.32M
Net Income/Loss:
$-184.46M
P/E Ratio:
-10.69
EPS:
-0.3415
Net Cash Flow:
$-264.08M
1W Performance:
+11.62%
1M Performance:
-3.18%
6M Performance:
-53.38%
1Y Performance:
-63.02%
1-Day Range:
$3.55
$3.6595
1-Week Range:
$3.3113
$3.6595
52-Week Range:
$2.85
$12.00
Evotec Se Adr Stock (EVO) Company Profile
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-18-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-23-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-08-23 | Upgrade | Citigroup | Neutral → Buy |
| Apr-04-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Dec-09-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Aug-10-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Jan-07-22 | Resumed | Citigroup | Neutral |
View All
Evotec Se Adr Stock (EVO) Latest News
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development - Benzinga
Stock Information - Evotec
Annual General Meeting - Evotec
Investor Relations - Evotec
Earnings call: Evotec SE reports revenue increase, plans cost cuts - Investing.com
Earnings call: Evotec SE revises 2024 outlook amid market challenges By Investing.com - Investing.com Canada
Earnings call: Evotec SE revises 2024 outlook amid market challenges - Investing.com
Earnings call: Evotec SE revises 2024 outlook amid market challenges By Investing.com - Investing.com UK
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar
Dozens of US Stocks Are Newly Undervalued After Market Selloff - Morningstar.ca
Evotec Faces Short-Term Headwinds and Rising Costs, but Long-Term Growth Outlook Remains Positive - Morningstar
Evotec shares crash 36% on profit warning - Investing.com
Antibody Discovery Market Size Expected to Surge to USD 4.8 - GlobeNewswire Inc.
Evotec stock holds Buy rating with price target from TD Cowen By Investing.com - Investing.com India
Evotec (OTCMKTS:EVTCY) Sets New 52-Week Low at $4.65 - Defense World
Financial Metrics Check: Evotec SE ADR (EVO)'s Ratios for Trailing Twelve Months – DWinneX - The Dwinnex
Healthcare Sector - Morningstar
Ratio Examination: Evotec SE ADR (EVO)'s Price-to-Cash and Price-to-Free Cash Flow – DWinneX - The Dwinnex
Evotec's Underlying Demand Looks Stable as Momentum Builds, but Some Market Challenges Linger - Morningstar
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com South Africa
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com India
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges By Investing.com - Investing.com
Earnings call: Evotec SE Q1 2024 results show mixed performance amid challenges - Investing.com Canada
Evotec gains R&D license from Centogene for Gaucher disease - Investing.com India
EQS-HV: Evotec SE: Bekanntmachung der Einberufung zur Hauptversammlung am 10.06.2024 in Hamburg mit dem ... - sharewise
Closing Bell Recap: Evotec SE ADR (EVO) Ends at 5.23, Reflecting a -31.63 Downturn – DWinneX - The Dwinnex
QT to end this December with hardly a whimper: Barclays By Investing.com - Investing.com
Dow Dips Over 100 Points; Ribbon Communications Shares Spike Higher By Benzinga - Investing.com UK
Evotec and Variant Bio partner to develop fibrosis treatments By Investing.com - Investing.com
T. Rowe Price Raises Stake in Evotec SE - TipRanks
Germany stocks mixed at close of trade; DAX down 0.03% By Investing.com - Investing.com
Germany stocks mixed at close of trade; DAX down 0.30% By Investing.com - Investing.com
Evotec, Defense Metals, Paypal – hier ist Bewegung, wo lohnt sich ein Einstieg? - INV3ST
Evotec: R&D, Customer Growth Not Enough To Offset Headwinds - Seeking Alpha
Stocks Climb Before the Open as Investors Weigh Economic Outlook, U.S. JOLTs Report in Focus - The Globe and Mail
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J - Yahoo Finance
Evotec SEADR Shares Near 52-Week LowMarket Mover - Nasdaq
EVOTECAktie konsolidiert weiterhin • news • onvista - onvista
A Peek Into The Markets: US Stock Futures Rise; J&J Secures Emergency Authorization for Covid-19 Vaccine - Benzinga
EVOTEC AKTIE | Aktienkurs | US30050E1055 | News | A0QZ3J | finanzen.net - finanzen.net
Evotec (EVTCY) Presents At Jefferies 2017 London Healthcare ConferenceSlideshow (NASDAQ:EVO) - Seeking Alpha
Together for Medicines That MatterEvotec Website (English) - Evotec
Evotech and Roche subsidiary Genentech enter into drug discovery alliance - Proactive Investors USA
Evotec Se Adr Stock (EVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):